Who Still Does Best With Surgery in the GLP-1 Era?
Eligibility rules tell you who gets on the ride, and the research tells you who tends to enjoy it.

I spent part of this week reading a 2026 systematic review that put weight-loss surgery and the new incretin drugs (semaglutide, tirzepatide and their relatives) side by side, and surgery won every category. Not narrowly. The review says surgery “demonstrated superiority over incretin-based therapies across all five primary outcome domains,” those being diabetes remission, weight reduction, heart attacks and deaths, fatty liver resolution and quality of life. It is a sweep, the kind of playoff series where the other team’s fans start talking about next season during game two.
So if you came here asking who qualifies for bariatric surgery, the plain answer is that eligibility is set by guidelines from the surgical societies, most recently the joint 2022 criteria from ASMBS and IFSO, which draw the weight and disease lines surgeons work from. The exact cutoffs are not in the sources behind this article, so I am not going to recite numbers I cannot point to. What those sources do answer is the more useful question, which is who does best once they are over the line. That answer depends a lot less on weight than you might guess.
What the rules for who qualifies for bariatric surgery can and can’t tell you
An eligibility rule is a height bar at an amusement park. It tells you who is allowed on the ride. It does not tell you who will enjoy it, who will throw up, or who will want to go again in four years.
That’s fine. Guidelines are supposed to be blunt. But it means two people who both clear the 2022 line can have very different odds, and the research on those odds is where the drug era actually changes things. Whether the 2022 criteria fully anticipated how good the newer drugs would get is not something these sources settle (the guidelines and the drugs were, roughly, moving at the same time).
There are, roughly, three ways to read the sweep
The first reading is the obvious one: surgery is just better. The numbers are not subtle. In that same 2026 review, surgery was associated with a pooled relative risk of major cardiac events of 0.48 compared with GLP-1 drugs (confidence interval 0.33 to 0.72), which means about half the risk. Sustained five-year weight loss was 25 to 32 percent with surgery against 14.9 to 20.9 percent with semaglutide or tirzepatide. A separate review of very long-term outcomes found that at ten years total weight loss ranged from 24.4 percent for the sleeve to about 40 percent for the duodenal switch (the site’s other articles go through each operation).
Then there is diabetes remission, where surgery achieved 23 to 70 percent and the drugs achieved 0 percent. Zero is a weird number. I feel like it deserves a moment.
Here is what remission means, in very plain words: your blood sugar looks like a non-diabetic person’s while you take no diabetes medicine. Doctors call this remission of type 2 diabetes. Notice the second half of that sentence. If the treatment is a diabetes medicine, then a person on it is, presumably, taking diabetes medicine, and so cannot be in remission by construction (that is my reading of the definition, not something the review spells out). The drug could produce perfect blood sugar forever and still score zero. It is a bit like a race where one runner is disqualified for wearing shoes.
None of that makes surgery’s lead fake. The cardiac and weight numbers do not have this problem. It just means one of the five categories is less of a contest than it looks.
The second reading: the drugs are the waiting room
The second reading says the sweep is the wrong frame because the two things are not really competing. A focused review on bariatric surgery and type 2 diabetes describes the drugs as possible “alternatives, bridges, or postoperative adjuncts” to surgery, then adds that “post-surgical evidence remains limited.” Alternatives, bridges, adjuncts. That is three jobs, and only one of them is rival.
The bridge job has some data. A single-center retrospective study screened 216 patients and analyzed 193, of whom 111 took a GLP-1 drug before surgery and 82 did not. The drug group lost more weight before the operation (median 9.0 kg against 5.0 kg) and had fewer major complications afterward (0 of 111 against 5 of 82, which is a small study and a small number of events). Measured from where everyone started, the drug group was ahead at 12 months, 34.5 percent total weight loss against 29.5 percent, and still slightly ahead at final follow-up, 37.8 against 35.1.
But measured from the day of surgery, weight, BMI and excess weight loss at three, six and twelve months did not differ between the groups at all. Diabetes and blood pressure remission at a year were similar too. This is a dinner bill where one friend counts the drinks he had at the bar before everyone sat down. His total is bigger. The dinner was the same dinner.
That is not a criticism of the study, which reports both anchors honestly. It just means the drug moved people forward in the queue rather than making the operation work better. The drug can also come after surgery: a double-blinded trial called BARI-STEP is testing semaglutide 2.4 mg weekly in adults with a disappointing response to surgery, and its results are not in these sources. One systematic review found that adding liraglutide to an endoscopic procedure produced weight loss comparable to surgery’s net weight loss once regain is subtracted, which is a sentence that does a lot of quiet work.
The third reading: surgery works best on people who need it least urgently
The third reading is the least comfortable, and it comes from asking who the surgical successes actually are.
An electronic-records cohort of 8,012 bariatric patients included 2,197 with type 2 diabetes before surgery. Of those, 2,056 (93.6 percent) got at least 90 days off diabetes medicine afterward, which is great. Then 882 of them, or 42.9 percent, started diabetes medicine again, at a median of about a year. In plain words: your pills went away, and then your pills came back. The researchers call this medication re-initiation following a medication-free interval. The study’s own title states the conclusion: “Baseline Diabetes Severity Is the Dominant Predictor.”
Longer diabetes duration raised the hazard of going back on medicine (1.219 per standard deviation). Using insulin before surgery raised it more (1.627). Gastric bypass did better than the sleeve (hazard ratio 0.778). Reviews of remission point the same direction: younger age, lower starting HbA1c, shorter duration, less treatment and better-preserved insulin-making cells all predict success, for surgery and for the drugs alike. Reported relapse rates after surgery run from about 10 percent to over 60 percent, which is less a range than a shrug.
The same pattern shows up in a smaller endoscopic procedure. A study applied a surgical scoring tool to endoscopic sleeve gastroplasty and found remission in 60 percent of mild cases, 45.5 percent of moderate ones and 0 percent of severe ones. Nothing is wrong with the patients or the surgeons here. Biology just keeps score early.
This produces a dumb-sounding but real conversation, which I am inventing: “Great news, you qualify. Quick question, how long have you had diabetes, and could it have been less?” The best surgical cohorts are, in the methods-section sense, selected, which is a neutral word in a paper and a slightly pointed one anywhere else.
So who still does best with surgery
Putting the readings together, the evidence here favors surgery most clearly for people with type 2 diabetes, especially earlier in the disease, and for outcomes like cardiac events and long-run weight where the drugs have not caught up in these data. Bypass looks more durable than the sleeve for diabetes. Drugs before surgery seem to change the starting line more than the finish. Whether drugs after surgery rescue the poor responders is not settled, or whatever the polite version of “the trial isn’t back yet” is.
I suppose that leaves the sweep standing, with an asterisk on the remission game and a note that the winning team plays best against opponents who have only just shown up. Taken one step further, the ideal surgical candidate, by the numbers, developed diabetes last Tuesday and is booked for Wednesday.
Sources
- Does Preoperative GLP-1 Therapy Improve Postoperative Bariatric Surgery Outcomes? A Single-Centre Retrospective Observational Study
- Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
- Lifestyle Modification and Bariatric Surgery in Type 2 Diabetes Remission : Short title: Diabetes Remission Strategies in T2DM
- Advances in Metabolic Bariatric Surgeries and Endoscopic Therapies: A Comprehensive Narrative Review of Diabetes Remission Outcomes
- Long-Term Effects of Bariatric Surgery on Type 2 Diabetes: Mechanisms, Outcomes, and Clinical Implications: A Focused Review
- Baseline Diabetes Severity Is the Dominant Predictor of Diabetes Medication Re-Initiation Following Bariatric Surgery
- Applicability of individualized metabolic surgery score for prediction of diabetes remission after endoscopic sleeve gastroplasty
- Bariatric Surgery and Type 2 Diabetes Remission and Relapse: Mechanisms, Predictive Factors, and Postoperative Management — a Review Article | Ciesielska | Clinical Diabetology
- A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
- Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.